Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice

Annals of General Psychiatry

Research

Nathalie Falsetto¹  Marco Micillo¹  Caterina Lobaccaro²  Miriam Olivola³  Lisa Lavatelli⁴  Antonello Bellomo⁵  Alessandro Cuomo⁶  Andrea Fagiolini⁷ 

[1] Angelini Pharma S.P.A, Viale Amelia70, 00181, Rome, Italy;Centro Salute Mentale Area 2 DSM ASL, Bari, Italy;Department of Brain and Behavioral Sciences, University of Pavia and Servizio Psichiatrico Di Diagnosi E Cura ASST Pavia, IRCCS Policlinico San Matteo, Viale Repubblica 34, 27100, Pavia, Italy;Psichiatria 1 ASST Grande Ospedale Metropolitano Niguarda, Piazza Dell’Ospedale Maggiore, 3, 20162, Milan, MI, Italy;University of Foggia, Viale Luigi Pinto, 1, 71122, Foggia, MI, Italy;University of Siena, V.Le Mario Bracci, 16, 53100, Siena, SI, Italy;Università Di Siena, V.Le Mario Bracci, 16, 53100, Siena (SI), Italy;

关键词: Schizophrenia;    Lurasidone;    Treatment persistence;   

DOI  :  10.1186/s12991-022-00425-y

 received in 2022-09-29, accepted in 2022-11-15,  发布年份 2022

来源: Springer

【 摘 要 】

Background and rationaleTreatment persistence combines clinician and patient judgment of efficacy, tolerability and safety into a comprehensive measure of effectiveness and is defined as the act of continuing a treatment over time. Studies have reported poor treatment persistence to antipsychotic medications in patients with schizophrenia. This study evaluated treatment persistence to lurasidone (LUR) in patients with schizophrenia in a real-world Italian setting.MethodsThis was a retrospective observational study of patients with schizophrenia who started treatment with LUR ≥ 6 months before inclusion. Following informed consent, data were collected starting from the index date (start of LUR treatment) at all visits occurring as per clinical practice. The primary endpoint was treatment persistence during the first 6 months, defined as the time between index date and all-cause discontinuation. Patients treated with LUR > 180 days were considered persistent. As secondary endpoint, treatment persistence was evaluated for a period of  ≥ 18 months.ResultsForty-five patients were enrolled and 41 (91.11%) completed the study. Forty-one patients (91.11%) were included in the eligible population as they initiated LUR treatment  ≥ 6 months before data collection.Patients were 43.0 ± 15.89 years old and 61% were female. Twenty-two patients (53.66%) started LUR treatment in a hospital setting and 19 (46.34%) in an outpatient setting. Based on Clinical Global Impression—Severity scale (CGI-S) at LUR initiation, 12 patients (29.27%) were severely ill, 17.07% markedly ill, 19.51% moderately ill, 2.44% mildly ill and 4.88% borderline mentally ill. Thirty-two patients (78.05%) were treatment persistent for  ≥ 180 days. Among the 19 patients observed for  ≥ 18 months, 11 (57.89%) were persistent for  ≥ 18 months. Among the 22 study patients observed for  < 18 months, 12 (54.54%) were persistent. An improvement in schizophrenia severity according to CGI-S was observed at inclusion (following LUR therapy) compared to the index date. Six patients (14.63%) experienced at least one adverse drug reaction: akathisia (7.32%), extrapyramidal disorder (4.88%), hyperprolactinemia (2.44%), restlessness (2.44%), and galactorrhea (2.44%). None were serious.ConclusionsPersistence to LUR in patients with schizophrenia was relatively high: 78% and 58% of patients were still on LUR after 6 and 18 months of treatment, respectively. This may reflect LUR’s relatively favorable balance between efficacy and tolerability, as well as favorable patient satisfaction and acceptance.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 1